Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL13Ralpha2 CAR T Cells in Metastatic Melanoma and Solid Tumors
NCT04119024Phase 1Recruiting
- Start
- Oct 2025
- Primary completion
- Oct 2026
- Modality
- Prophylactic Vaccines, CAR-T Cells, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IL13Ralpha2 hinge-optimized 41BB CAR truncated CD19-expressing autologous T-cells in melanoma and solid tumor. Primary endpoints: Incidence of adverse events up to 90 days and Dose-limiting toxicity up to 28 days. Started Oct 2025; status: recruiting.
02
Drugs
IL13Ralpha2 hinge-optimized 41BB CAR truncated CD19-expressing autologous T-cells
03
Conditions
melanomasolid tumor
Beyond the preview
Go deeper on NCT04119024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04119024.